Help paying · Medicare negotiated price · pharmacy cost · cycle 2026
Enbrel (etanercept): where help paying exists, what Medicare negotiated and what pharmacies pay
2 assistance programs list etanercept, each with its income ceiling and when we read it. Medicare's negotiated price for a 30-day supply is $2,355 (in force since January 1, 2026). A scheduled change takes it to $2,419 on January 1, 2027. Per unit, the negotiated price is 28% of NADAC, the pharmacy acquisition benchmark. 3 non-manufacturing label changes are dated in the last 12 months in the FDA's file. The FDA's enforcement reports name this drug's packages in 1 recall entry. ClinicalTrials.gov lists 13 recruiting trials that name etanercept.
One package, side by side
Price per unit for one package of Enbrel. The negotiated price applies to Medicare Part D; NADAC is a survey of what retail pharmacies pay to buy the drug.
Swipe to read across
Every package we can price
Per-unit prices (per mL, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 58406-0010-01 | ENBREL (etanercept) | n/a | $584 | $599 | n/a | no NADAC price |
| 58406-0010-04 | ENBREL (etanercept) | ML | $584 | $599 | $2,084 | 28% |
| 58406-0021-01 | ENBREL (etanercept) | n/a | $584 | $599 | n/a | no NADAC price |
| 58406-0021-04 | ENBREL (etanercept) | ML | $584 | $599 | $2,081 | 28% |
| 58406-0032-01 | ENBREL (etanercept) | n/a | $584 | $600 | n/a | no NADAC price |
| 58406-0032-04 | ENBREL (etanercept) | ML | $584 | $600 | $2,084 | 28% |
| 58406-0044-01 | ENBREL (etanercept) | n/a | $584 | $599 | n/a | no NADAC price |
| 58406-0044-04 | ENBREL (etanercept) | ML | $584 | $599 | $2,082 | 28% |
| 58406-0044-24 | (name not listed) | ML | $584 | $599 | $2,082 | 28% |
| 58406-0055-01 | ENBREL (etanercept) | n/a | $582 | $598 | n/a | no NADAC price |
| 58406-0055-04 | ENBREL (etanercept) | n/a | $582 | $598 | n/a | no NADAC price |
| 58406-0425-34 | ENBREL (etanercept) | n/a | $288 | $296 | n/a | no NADAC price |
| 58406-0425-41 | ENBREL (etanercept) | n/a | $288 | $296 | n/a | no NADAC price |
| 58406-0435-01 | ENBREL (etanercept) | n/a | $584 | $599 | n/a | no NADAC price |
| 58406-0435-04 | ENBREL (etanercept) | n/a | $584 | $599 | n/a | no NADAC price |
| 58406-0445-01 | ENBREL (etanercept) | n/a | $584 | $600 | n/a | no NADAC price |
| 58406-0445-04 | ENBREL (etanercept) | n/a | $584 | $600 | n/a | no NADAC price |
| 58406-0446-01 | (name not listed) | n/a | $584 | $600 | n/a | no NADAC price |
| 58406-0446-04 | (name not listed) | n/a | $584 | $600 | n/a | no NADAC price |
| 58406-0455-01 | ENBREL (etanercept) | n/a | $584 | $599 | n/a | no NADAC price |
| 58406-0455-04 | ENBREL (etanercept) | n/a | $584 | $599 | n/a | no NADAC price |
| 58406-0456-01 | ENBREL (etanercept) | n/a | $584 | $599 | n/a | no NADAC price |
| 58406-0456-04 | ENBREL (etanercept) | n/a | $584 | $599 | n/a | no NADAC price |
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Enbrel of $632.79 million in 2024, across 80,845 claims and 10,542 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $632.79 million | 80,845 | 10,542 | $7,827 |
| 2023 | $627.42 million | 81,987 | 10,678 | $7,653 |
| 2022 | $612.02 million | 85,310 | 11,311 | $7,174 |
| 2021 | $590.85 million | 88,581 | 12,049 | $6,670 |
| 2020 | $583.37 million | 90,789 | 12,573 | $6,426 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Biosimilar status
- Enbrel; Enbrel Mini (etanercept) is a reference product in the FDA Purple Book (BLA 103795, approved November 2, 1998). The Purple Book lists 1 biosimilar and 1 interchangeable product that name it as their reference product.
Biosimilars: Erelzi; Erelzi Sensoready, approved August 30, 2016
Interchangeable: Eticovo, interchangeable since June 25, 2024
This is what the FDA Purple Book lists on the read date. It is a record, not a forecast of when any product will launch or be substituted.
Source: FDA Purple Book (purplebook-2026-10), read November 7, 2026. Purple Book data file.
FDA safety program (REMS)
- Enbrel (application BLA103795): listed as released, without Elements to Assure Safe Use. Program dated June 23, 2008, last modified August 10, 2011. REMS@FDA program page.
A REMS is a safety program the FDA can require for a drug. Some restrict how it is prescribed or dispensed, for example through certified prescribers or pharmacies. This lists what the FDA's REMS@FDA files tie to the application; it does not say which prescribers or pharmacies take part, or whether a given patient needs the program.
Source: FDA REMS@FDA data files (rems-fda-files-2026-11-07-products-20a9945448dd), read November 7, 2026. REMS@FDA product file.
Rare-disease (orphan) designations
The FDA's orphan drug database lists 2 designations for Etanercept; etanercept, 1 with an approval recorded. A designation is not an approval and not a statement that the drug treats the condition; the status column is the database's own.
| Designated | Designated use | Status | Sponsor |
|---|---|---|---|
| April 6, 1999 | Treatment of Wegener's granulomatosis. | Designated/Designation Withdrawn or Revoked | Immunex Corporation |
| October 27, 1998 | Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying ant (cut at 200 characters) | Designated/Approved | Immunex Corporation |
Source: FDA Orphan Drug Designations and Approvals database, read November 7, 2026. FDA orphan drug search.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 10 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| NC | 142 | $878,373 | All record types |
| UT | 83 | $720,784 | Fee-for-service only |
| OH | 118 | $696,817 | Fee-for-service only |
| NV | 76 | $610,523 | Fee-for-service only |
| AZ | 96 | $517,725 | All record types |
| OR | 61 | $460,408 | Fee-for-service only |
| GA | 56 | $361,508 | Fee-for-service only |
| PR | 73 | $349,698 | All record types |
| MO | 61 | $333,377 | All record types |
| TN | 55 | $228,567 | All record types |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (5 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 155 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
Programs in our finder that list etanercept. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- Amgen Safety Net Foundation manufacturer
Income at or below $47,880 for one person (300% FPL), and no insurance coverage
Limit read October 19, 2026. - TAF Cares (The Assistance Fund) nonprofit
Income at or below 500% of the poverty level
Figure not yet re-read on the program's own page.
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
FDA actions on the applications behind Enbrel dated since November 11, 2025, leaving out manufacturing (CMC) changes. 3 changes in the window.
| Date | Class | Application | Submissions | FDA documents |
|---|---|---|---|---|
| October 14, 2026 | Labeling | BLA103795 | 5610 | FDA letter posted October 16, 2026 |
| January 30, 2026 | Labeling | BLA103795 | 5605 | Label (PDF) posted February 6, 2026FDA letter posted February 3, 2026 |
| December 10, 2025 | Labeling | BLA103795 | 5604 | FDA letter posted December 11, 2025 |
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Safety notices
FDA enforcement report entries that name a package of Enbrel by its NDC: 1 entry, newest first. FDA assigns each a class by health risk: Class I is the most serious and Class III the least. An entry records what the recalling firm reported and FDA classified; it is not advice about any package you hold.
| Reported | Class | Status | Recalling firm | Reason (shortened) | Packages named |
|---|---|---|---|---|---|
| May 16, 2018D-0746-2018 | Class II | Terminated | Kroger Specialty Pharmacy, Inc. | Lack of Processing Controls. | 1 |
Source: openFDA drug enforcement reports, file read November 7, 2026. openFDA data file. All recent recalls across these drugs: drug recalls feed.
Clinical trials recruiting
ClinicalTrials.gov lists 13 interventional trials that name etanercept and are recruiting, and 2 more not yet recruiting. By phase: Phase 4: 6, Phase 3: 2, Not applicable: 2, Phase 2: 1, Phase 1: 1, PHASE2/PHASE3: 1. The 10 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT06654882 | Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisPolyarticular Course Juvenile Idiopathic Arthritis (JIA) | Phase 3 | Duke University | October 21, 2026 | United States, Germany, Italy and 1 more |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRheumatic Disease | Phase 2 | NYU Langone Health | July 9, 2026 | United States |
| NCT07184853 | Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHDGraft vs Host Disease | Not applicable | First Affiliated Hospital of Zhejiang University | July 7, 2026 | China |
| NCT03414502 | Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRheumatoid Arthritis | Phase 3 | University of Nebraska | June 17, 2026 | United States |
| NCT06585384 | Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's DiseaseAlzheimer Disease | Phase 1 | Fondation Ophtalmologique Adolphe de Rothschild | May 12, 2026 | France |
| NCT06011889 | Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO SyndromeSAPHO Syndrome | Phase 2 / Phase 3 | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | April 13, 2026 | Poland |
| NCT05305066 | Stand UP to Rheumatoid Arthritis (SUPRA)Rheumatoid Arthritis | Not applicable | Marie Hudson, MD | February 3, 2026 | Canada |
| NCT07149792 | A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular BiomarkersPsoriasis; Psoriasis Arthritis; Biologics | Phase 4 | Taichung Veterans General Hospital | September 2, 2025 | Taiwan |
| NCT04985435 | Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)Rheumatoid Arthritis | Phase 4 | R.Bos | August 8, 2025 | Netherlands |
| NCT06707194 | Effect and Safety of Benzathine Penicillin Combined With Etanercept on SpondyloarthritisSpondyloarthritis (SpA); Ankylosing Spondylitis (AS) | Phase 4 | Nanfang Hospital, Southern Medical University | June 26, 2025 | China |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Enbrel?
For a 30-day supply the price CMS published is $2,355, in force since January 1, 2026. The CMS file also schedules $2,419 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
Across the 5 packages where both CMS files give a price per unit, the median negotiated price is 28% of NADAC, the pharmacy acquisition benchmark (NADAC as of November 4, 2026). NADAC is a survey average, not a quote.
Is there help paying for Enbrel?
2 assistance programs list it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
Can I join a clinical trial for Enbrel?
ClinicalTrials.gov lists 13 recruiting interventional trials that name etanercept (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Enbrel?
CMS's Medicare Part D spending dataset reports gross spending on Enbrel of $632.79 million in 2024, across 80,845 claims and 10,542 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/enbrel.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Purple Book; FDA Drugs@FDA and Orange Book data files; openFDA drug enforcement reports; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.